Surrogate binding proteins which bind DR4 and/or DR5
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07K-016/28
A61K-039/395
A61K-045/06
C07K-016/30
A61K-039/00
출원번호
US-0367862
(2012-12-21)
등록번호
US-9975956
(2018-05-22)
국제출원번호
PCT/US2012/071352
(2012-12-21)
국제공개번호
WO2013/096828
(2013-06-27)
발명자
/ 주소
Kashyap, Arun K.
Bhatt, Ramesh R.
Horowitz, Michael
Horowitz, Lawrence
Zhou, Sihong
O'Neil, Ryann E.
Hannum, Charles H.
Kurtzman, Aaron L.
Xu, Li
출원인 / 주소
i2 PHARMACEUTICALS, INC.
대리인 / 주소
Cooley LLP
인용정보
피인용 횟수 :
0인용 특허 :
59
초록
Embodiments concern constructs comprising surrogate light chain sequences. In particular, embodiments concern constructs that can bind to DR4 and/or DR5 and aspects relating to such constructs and their use.
대표청구항▼
1. A sur-binding protein (SBP) comprising: (i) a surrogate light chain (SLC) sequence comprising, from N-terminus to C-terminus, a VpreB sequence conjugated to a λ5 sequence,wherein the VpreB sequence comprises an amino acid sequence that is at least 90% identical to a native VpreB sequence of SEQ I
1. A sur-binding protein (SBP) comprising: (i) a surrogate light chain (SLC) sequence comprising, from N-terminus to C-terminus, a VpreB sequence conjugated to a λ5 sequence,wherein the VpreB sequence comprises an amino acid sequence that is at least 90% identical to a native VpreB sequence of SEQ ID NOs: 1-4, or fragments thereof which lack the C-terminal peptide extension of the native VpreB sequence,wherein the λ5 sequence comprises an amino acid sequence that is at least 90% identical to a native λ5 sequence of SEQ ID NOs: 5 or 6, or fragments thereof which lack the N-terminal peptide extension of the native λ5 sequence; and(ii) a heavy chain variable region amino acid sequence that is paired with the SLC to form an SBP, wherein the heavy chain variable region amino acid sequence comprises (a) a heavy chain complementarity determining region (CDR) 1 sequence comprising SEQ ID NO: 39, a heavy chain CDR2 sequence comprising SEQ ID NO: 40, and a heavy chain CDR3 sequence comprising SEQ ID NO: 41; or(b) a heavy chain CDR1 sequence comprising SEQ ID NO: 459, a heavy chain CDR2 sequence comprising SEQ ID NO: 460, and a heavy chain CDR3 sequence comprising SEQ ID NO: 461,wherein said SBP binds to DR4, DR5, or DR4 and DR5. 2. The SBP of claim 1, wherein the SBP binds to DR5 and displaces TRAIL. 3. The SBP of claim 1, wherein the SBP binds to DR4 and DR5. 4. The SBP of claim 1, wherein the SBP selectively binds to DR5 when DR5 is expressed with DR4. 5. The SBP of claim 1, wherein the C-terminus of the VpreB sequence is conjugated to the N terminus of the λ5 sequence by direct fusion. 6. The SBP of claim 5, wherein the C-terminus of the VpreB sequence is directly fused to N terminus of the λ5 sequence at or around a LR3 region of the VpreB sequence. 7. The SBP of claim 5, wherein at least one of the VpreB sequence or λ5 sequence is other than a full-length native VpreB sequence or λ5 sequence, respectively. 8. The SBP of claim 5, wherein the N-terminus of the VpreB sequence is non-covalently conjugated to the heavy chain variable region amino acid sequence to form a dimeric complex. 9. The SBP of claim 1, wherein the VpreB sequence is conjugated to the λ5 sequence by a non-covalent association, and wherein at least one of the VpreB sequence or λ5 sequence is other than a full-length native VpreB sequence or λ5 sequence, respectively. 10. The SBP of claim 9, wherein the N-terminus of the VpreB sequence is covalently conjugated to the heavy chain variable region amino acid sequence to form a dimeric complex. 11. A bispecific sur-binding protein (SBP) comprising: (a) a first dimeric complex comprising (i) a first surrogate light chain (SLC) sequence comprising, from N-terminus to C-terminus a first VpreB sequence conjugated to a first λ5 sequence; and(ii) a first heavy chain variable region amino acid sequence that is paired with the first SLC sequence to form a first SBP binding site, wherein the first SBP binding site binds to a first target that is a DR4 and/or DR5 receptor; and(b) a second dimeric complex comprising (i) a second SLC sequence comprising, from N-terminus to C-terminus, a second VpreB sequence conjugated to a second λ5 sequence; and(ii) a second heavy chain variable region amino acid sequence that is paired with the second SLC sequence to form a second SBP site, wherein said second SBP site binds to a second target,wherein the first heavy chain variable region amino acid sequence comprises a heavy chain CDR1 sequence comprising SEQ ID NO: 39, a heavy chain CDR2 sequence comprising SEQ ID NO: 40, and a heavy chain CDR3 sequence comprising SEQ ID NO: 41, ora heavy chain CDR1 sequence comprising SEQ ID NO: 459, a heavy chain CDR2 sequence comprising SEQ ID NO: 460, and a heavy chain CDR3 sequence comprising SEQ ID NO: 461 , andwherein the first and second VpreB sequences comprise an amino acid sequence that is at least 90% identical to a native VpreB sequence of SEQ ID NOs: 1-4, or fragments thereof which lack the C-terminal peptide extension of the native VpreB sequence, and the first and second λ5 sequences comprise an amino acid sequence that is at least 90% identical to a native λ5 sequence of SEQ ID NO: 5 or 6, or fragments thereof which lack the N-terminal peptide extension of the native λ5 sequence. 12. The bi-specific SBP of claim 11, wherein (a) the C-terminus of the first VpreB sequence is conjugated to the N-terminus of the first λ5 sequence by direct fusion at or around a LR3 region of the first VpreB sequence, and;(b) the C-terminus of the second VpreB sequence is conjugated to the N-terminus of the second λ5 sequence by direct fusion at or around a LR3 region of the second VpreB sequence,wherein at least one of the first VpreB or first λ5 sequence and at least one of the second VpreB or second λ5 sequence is a sequence other than a full-length native VpreB or λ5 sequence, respectively. 13. The bi-specific SBP of claim 12, wherein (a) the N-terminus of the first VpreB sequence is non-covalently conjugated to the first heavy chain variable region amino acid sequence to form the first dimeric complex, and;(b) the N-terminus of the second VpreB sequence is non-covalently conjugated to the second heavy chain variable region amino acid sequence to form the second dimeric complex. 14. The bi-specific SBP of claim 11, wherein (a) the C-terminus of the first VpreB sequence is non-covalently conjugated to the N-terminus of the first λ5 sequence, and;(b) the C-terminus of the second VpreB sequence is non-covalently conjugated to the N-terminus of the second λ5 sequence,wherein at least one of the first VpreB or first λ5 sequence and at least one of the second VpreB or second λ5 sequence is a sequence other than a full-length native VpreB or λ5 sequence, respectively. 15. The bi-specific SBP of claim 14 wherein (a) the N-terminus of the first VpreB sequence is covalently conjugated to the first heavy chain variable region amino acid sequence to form the first dimeric complex, and;(b) the N-terminus of the second VpreB sequence is covalently conjugated to the second heavy chain variable region amino acid sequence to form the second dimeric complex.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (59)
Akimoto Hiroshi (Kobe JPX) Kawai Akiyoshi (Kobe JPX), 4,5-Deoxymaytansinoids, their use and pharmaceutical compositions thereof.
Zhao, Robert Yongxin; Miller, Michael Louis; Widdison, Wayne Charles; Chari, Ravi V. J., Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same.
Chari Ravi J. (Boston MA) Goldmacher Victor S. (Newton Center MA) Lambert John M. (Cambridge MA) Blattler Walter A. (Brookline MA), Cytotoxic agents comprising maytansinoids and their therapeutic use.
Chari Ravi J. (Boston MA) Goldmacher Victor S. (Newton Center MA) Lambert John M. (Cambridge MA) Blattler Walter A. (Brookline MA), Cytotoxic agents comprising maytansinoids and their therapeutic use.
La Zor Clair G. (13054 Rose St. Cerritos CA 90701), Instrument for locating faults in aircraft passenger reading light and attendant call control system.
Kraus Matthias H. (Bethesda MD) Aaronson Stuart A. (Vienna VA), Isolated polypeptide erbB-3, related to the epidermal growth factor receptor and antibody thereto.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhancing transmembrane transport of exogenous molecules.
Loughrey Helen C. (Vancouver CAX) Cullis Pieter R. (Vancouver CAX) Bally Marcel B. (Bowen Island CAX) Choi Lewis S. (Burnaby CAX), Method for protein-liposome coupling.
Freedman Bernard (Peoria IL) Powell Richard G. (Peoria IL) Smith ; Jr. Cecil R. (Dunlap IL), Method of controlling the European corn borer with trewiasine.
Steeves, Rita M.; Chari, Ravi V. J.; Blattler, Walter A., Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Bauer Steven R. (Birsfelden CHX) Kudo Akira (Basel CHX) Melchers Georg F. (Grenzach DEX) Sakaguchi Nobuo (Saga JPX), Nucleotide sequences which are selectively expressed in pre-B cells and probes therefor.
Mullis Kary B. (La Jolla CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or cloning nucleic acid sequences.
Mullis Kary B. (La Jolla CA) Erlich Henry A. (Oakland CA) Gelfand David H. (Oakland CA) Horn Glenn (Emeryville CA) Saiki Randall K. (Richmond CA), Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme.
Carlsson Jan P. E. (Upsala SEX) Axn Rolf E. A. V. (Blinge SEX) Drevin Hakan N. Y. (Brunna SEX) Lindgren Gran E. S. (Almunge SEX), Pyridine compounds modifying proteins, polypeptides or polysaccharides.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
Eppstein Deborah A. (Los Altos CA) Fraser-Smith Elizabeth B. (Los Altos CA) Matthews Thomas R. (Los Gatos CA), Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
Willner David (Hamden CT) Trail Pamela A. (Farmington CT) King H. Dalton (Hamden CT) Hofstead Sandra J. (Middletown CT) Greenfield Robert S. (Wallingford CT) Braslawsky Gary R. (Glastonbury CT), Thioether conjugates.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.